Bibliographic Details
Title: |
Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort. |
Authors: |
Denton, Eve, Hew, Mark, Peters, Matthew J., Upham, John W., Bulathsinhala, Lakmini, Tran, Trung N., Martin, Neil, Bergeron, Celine, Al‐Ahmad, Mona, Altraja, Alan, Larenas‐Linnemann, Désirée, Murray, Ruth, Celis‐Preciado, Carlos Andrés, Al‐Lehebi, Riyad, Belhassen, Manon, Bhutani, Mohit, Bosnic‐Anticevich, Sinthia Z., Bourdin, Arnaud, Brusselle, Guy G., Busby, John |
Source: |
Allergy; Oct2024, Vol. 79 Issue 10, p2700-2716, 17p |
Subject Terms: |
FORCED expiratory volume, ASTHMATICS, RANDOMIZED controlled trials, BIOTHERAPY, MONOCLONAL antibodies |
Abstract: |
Background: Biologic asthma therapies reduce exacerbations and long‐term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real‐world population of adults with severe asthma. Methods: Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow‐up were grouped into those who did, or did not, initiate biologics (anti‐IgE, anti‐IL5/IL5R, anti‐IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super‐response criteria were: FEV1 increase by ≥500 mL, new well‐controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day. Results: 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non‐initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super‐responses. Responses/super‐responses were more frequent in biologic initiators than in non‐initiators; nevertheless, ~40–50% of initiators did not meet response criteria. Conclusions: Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non‐initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super‐responses in all outcome domains, 40–50% did not meet the response criteria. [ABSTRACT FROM AUTHOR] |
|
Copyright of Allergy is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
Database: |
Complementary Index |